Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 266

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis

Stokes, Michael B., Foster, Kirk, Markowitz, Glen S., Ebrahimi, Farhang, Hines, William, Kaufman, Darren, Moore, Brooke, Wolde, Daniel, D'Agati, Vivette D. · 2005 · Nephrology Dialysis Transplantation

Abstract

BACKGROUND: Treatment of rheumatoid arthritis with anti-tumour necrosis factor alpha (TNFalpha) agents may lead to autoantibody formation and flares of vasculitis, but renal complications are rare. METHODS: We report the clinical and pathologic findings in five patients with longstanding rheumatoid arthritis (duration of rheumatoid arthritis, 10-30 years; mean, 23 years) who developed new onset of glomerular disease after commencing therapy with anti-TNFalpha agents (duration of therapy, 3-30 months; median, 6 months). RESULTS: At presentation, three patients were receiving etanercept, one adalimumab and one infliximab. Two subjects presented with acute renal insufficiency, haematuria, nephrotic-range proteinuria, positive lupus serologies, and hypocomplementemia, and renal biopsies showed proliferative lupus nephritis. Two individuals presented with new onset renal insufficiency, haematuria and proteinuria, and renal biopsies showed pauci-immune necrotizing and crescentic glomerulonephritis. One of these subjects, who had anti-myeloperoxidase autoantibodies, also developed pulmonary vasculitis. The fifth patient presented with nephrotic syndrome and renal biopsy findings of membranous glomerulonephritis, associated with immune complex renal vasculitis. A pathogenic role for anti-TNFalpha therapy is suggested by the close temporal relationship with development of glomerular disease, and by the improvement in clinical and laboratory abnormalities after drug withdrawal and initiation of immunosuppressive therapy in most cases. CONCLUSIONS: Rheumatoid arthritis patients receiving anti-TNFalpha agents may develop glomerulonephritis via the induction of rheumatoid arthritis-related nephropathy or de novo autoimmune disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ndt/gfh832

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 266

Metadata

Authors
Stokes, M. B., Foster, K., Markowitz, G. S., Ebrahimi, F., Hines, W., Kaufman, D., Moore, B., Wolde, D., & D'Agati, V. D.
Venue
Nephrology Dialysis Transplantation
Published
2005-04-19
Volume
20
Issue
7
Pages
1400-1406
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
OpenAlex
W2125346357
Cited by
266
References
17
FWCI
11.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. https://app.cochat.ai/papers/10.1093/ndt/gfh832
The paper
Stokes, M. B., Foster, K., Markowitz, G. S., Ebrahimi, F., Hines, W., Kaufman, D., Moore, B., Wolde, D., & D'Agati, V. D. (2005). Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfh832

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.